Clinical Trial Update: Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating local budesonide therapy for hyposmia in non-severe COVID-19 patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anosmia
• Hyposmia

Drugs mentioned

• Budesonide (BUDESONIDE)

Snippet

Sponsor: Fondation Ophtalmologique Adolphe de Rothschild | Conditions: Budesonide, Olfaction Disorders | Phase 3 | Status: COMPLETED